You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

gilteritinib

Showing 26 - 42 of 42
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations Trial in Canada, Japan, United States (gilteritinib)

Approved for marketing
  • Acute Myeloid Leukemia (AML)
  • FMS-like Tyrosine Kinase-3 (FLT3) Mutations
  • gilteritinib
  • Los Angeles, California
  • +38 more
Apr 18, 2021

Leukemia, Myeloid, Acute Trial in Worldwide (CC-90009, Venetoclax, Azacitidine)

Recruiting
  • Leukemia, Myeloid, Acute
  • San Francisco, California
  • +25 more
Jan 9, 2023

Acute Myeloid Leukemia Trial in Canada, Puerto Rico, United States (procedure, drug, behavioral)

Recruiting
  • Acute Myeloid Leukemia
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +13 more
  • Birmingham, Alabama
  • +187 more
Apr 28, 2022

Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia Trial in Japan, Korea, Republic of, Taiwan (gilteritinib,

Active, not recruiting
  • Acute Myeloid Leukemia
  • FLT3-mutated Acute Myeloid Leukemia
  • gilteritinib
  • +2 more
  • Anjo, Aichi, Japan
  • +54 more
Jan 10, 2023

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide (gilteritinib, LoDAC (Low Dose

Active, not recruiting
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
  • gilteritinib
  • +3 more
  • Beijing, China
  • +47 more
Aug 17, 2022

Leukemia, Acute Myeloid (AML) Trial in Worldwide (gilteritinib, LoDAC (Low Dose Cytarabine), Azacitidine)

Active, not recruiting
Has Results
  • Leukemia, Acute Myeloid (AML)
  • gilteritinib
  • +4 more
  • Birmingham, Alabama
  • +125 more
Aug 9, 2022

Advanced Solid Tumors, Pharmacokinetics of 14C-labeled Gilteritinib Trial in Cleveland (gilteritinib, 14C-labeled gilteritinib)

Completed
  • Advanced Solid Tumors
  • Pharmacokinetics of 14C-labeled Gilteritinib
  • gilteritinib
  • 14C-labeled gilteritinib
  • Cleveland, Ohio
    Site US10001
Mar 13, 2019

Optimize Treatment Strategies for Older Hematologic Malignancies

Recruiting
  • Leukemia, Acute
  • MDS
  • Bone Marrow or Peripheral Blood Graft (BMT)
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 7, 2022

Acute Myeloid Leukemia, MDS Trial in United States (CG-806)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Duarte, California
  • +9 more
Mar 4, 2022

Acute Myeloid Leukemia (AML) Trial in France

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
    • Amiens, France
    • +28 more
    Jul 21, 2021

    Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations Trial in Australia, Italy, United Kingdom

    No longer available
    • Acute Myeloid Leukemia (AML)
    • FMS-like Tyrosine Kinase-3 (FLT3) Mutations
    • gilteritinib
    • Canberra, Australia
    • +5 more
    Sep 12, 2018

    Acute Myeloid Leukemia Trial in Germany, Italy, United States (Gilteritinib, Voriconazole, Midazolam)

    Completed
    Has Results
    • Acute Myeloid Leukemia
    • Gilteritinib
    • +3 more
    • Birmingham, Alabama
    • +25 more
    May 9, 2019

    Non-Small-Cell Lung Cancer Trial in Japan (Gilteritinib, Erlotinib)

    Terminated
    Has Results
    • Non-Small-Cell Lung Cancer
    • Fukuoka Minami-ku, Fukuoka, Japan
    • +3 more
    Jan 21, 2019

    Acute Myeloid Leukemia (AML) Trial in Japan (Gilteritinib)

    Completed
    • Acute Myeloid Leukemia (AML)
    • Gilteritinib
    • Aichi, Japan
    • +4 more
    Dec 20, 2018

    AML Trial in Los Angeles (ASP2215)

    No longer available
    • AML
    • Los Angeles, California
      Children's Hospital Los Angeles
    Apr 13, 2018

    Advanced Solid Tumors Trial in Nanjing (Anlotinib and 14C-labeled Anlotinib)

    Completed
    • Advanced Solid Tumors
    • Anlotinib and 14C-labeled Anlotinib
    • Nanjing, Jiangsu, China
      Jiangsu Province Hospital
    Apr 27, 2019

    Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse Trial in

    Unknown status
    • Acute Lymphoblastic Leukemia Recurrent
    • +4 more
    • INA03 administration
    • Marseille, Bouches-du Rhône, France
    • +1 more
    Feb 4, 2020